RxDoctor Payments Data

Kimberly Champney, MD

Cardiovascular Disease · Atlanta, GANPI 1881740959

Payments from drug & device makers

$3,551in general payments, 2019–2025

Across 182 payments — averaging $19.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$616
  • Pfizer$504
  • Amgen$443
  • Johnson & Johnson$336
  • Boehringer Ingelheim$311
  • AstraZeneca$215
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$3,53299%
  • Education$191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,551 in reported general payments places this provider in the 55th percentile of 640 cardiovascular disease providers in Georgia.

See all cardiovascular disease providers in Georgia

Medicare billing

Part B allowed, 2024
$156,843
Medicare patients
960
Services billed
2,300

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban472$512,782
XareltoRivaroxaban102$116,958
EntrestoSacubitril/Valsartan49$57,667
Repatha SureclickEvolocumab55$44,251
JardianceEmpagliflozin29$30,898
Repatha SyringeEvolocumab28$17,711
Praluent PenAlirocumab11$13,497
Nebivolol Hcl45$4,717
Ezetimibe146$4,367
Metoprolol Succinate321$4,235
Rosuvastatin Calcium363$3,917
Atorvastatin Calcium404$3,544
Amlodipine Besylate496$2,524
Losartan Potassium261$2,169
Carvedilol180$1,592

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$504$512,782472 claims
Johnson & JohnsonXarelto$336$116,958102 claims
NovartisEntresto$616$57,66749 claims
Boehringer IngelheimJardiance$311$30,89829 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 640 cardiovascular disease providers in Georgia.

Other cardiovascular disease in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →